EssilorLuxottica Unsponsored ADR (OTCMKTS:ESLOY) Receives Consensus Rating of “Buy” from Analysts

Shares of EssilorLuxottica Unsponsored ADR (OTCMKTS:ESLOY) have received a consensus rating of “Buy” from the eight analysts that are currently covering the stock, MarketBeat reports. One research analyst has rated the stock with a hold recommendation, five have given a buy recommendation and two have issued a strong buy recommendation on the company.

Several research firms have recently weighed in on ESLOY. Royal Bank Of Canada reissued an “outperform” rating on shares of EssilorLuxottica in a report on Tuesday, October 28th. UBS Group upgraded shares of EssilorLuxottica from a “hold” rating to a “strong-buy” rating in a research note on Thursday, November 27th. Kepler Capital Markets raised EssilorLuxottica from a “hold” rating to a “buy” rating in a report on Thursday, January 15th. Citigroup reaffirmed a “buy” rating on shares of EssilorLuxottica in a report on Thursday, December 11th. Finally, Zacks Research cut EssilorLuxottica from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, November 18th.

EssilorLuxottica Stock Performance

Shares of OTCMKTS:ESLOY opened at $138.93 on Tuesday. The company has a debt-to-equity ratio of 0.18, a current ratio of 0.97 and a quick ratio of 0.67. The business has a 50-day simple moving average of $155.58 and a two-hundred day simple moving average of $163.33. EssilorLuxottica has a fifty-two week low of $126.47 and a fifty-two week high of $186.81.

About EssilorLuxottica

EssilorLuxottica SE is a global ophthalmic optics company formed through the 2018 merger of France-based Essilor and Italy-based Luxottica. Headquartered near Paris, the company combines lens manufacturing, frame design and production, brand management and retail operations to provide a vertically integrated offering across the vision care value chain. Its activities span product research and development, manufacturing, wholesale distribution and retailing of spectacles, sunglasses and ophthalmic lenses.

The company’s product portfolio includes prescription and non-prescription lenses, lens coatings and treatments, and an array of eyewear brands and frames.